A new blood test that measures a specific protein may predict the likelihood of Alzheimer’s-related cognitive decline long before symptoms emerge. Presented at the Alzheimer’s Association International Conference (AAIC) 2026 in London, research indicates that older adults with high levels of the biomarker p-tau217 have a 78% chance of developing cognitive impairment within a decade, even when they show no current memory or thinking issues.
Currently, nearly 7 million Americans live with Alzheimer’s disease, and forecasts by the Alzheimer’s Association suggest this could reach 13 million by 2050 without medical advancements.
Promises and Cautions
Dr. Manisha Parulekar from Hackensack University Medical Center emphasizes the potential of this blood test in transforming Alzheimer’s risk assessment. Shifting risk detection from specialized clinics to primary care settings could lead to early interventions, addressing factors like blood pressure and physical activity. Additionally, it would enhance recruitment efforts for preventive trials by determining if early intervention can delay the disease.
However, Dr. Parulekar warns about possible psychological impacts following a positive result, including anxiety and grief. Concerns exist regarding insurance discrimination and access disparities, highlighting the need for responsible test implementation with counseling and equitable intervention access.
Details from the Study
The study analyzed blood samples from nearly 2,700 cognitively healthy adults, averaging 70 years of age, collected from six major Alzheimer’s research groups. This large-scale research followed participants for almost five years on average, with some tracked for over a decade, using memory, thinking, and daily function tests.
Adults displaying p-tau217 levels more than twice the study average had a 78% risk of cognitive impairment within ten years and a 38% risk within five years. Moderately elevated levels still had significant risks: about 15% over five years and 45% over ten years. The blood test provided predictive value beyond what existing brain scans and genetic tests could offer.
P-tau217 is a modified form of the tau protein, known for forming brain tangles associated with Alzheimer’s, and is linked to amyloid beta levels, making it a comprehensive marker for the disease processes.
Rachel F. Buckley, the study’s lead author, stated that elevated p-tau217 levels might detect dementia risk earlier, even in those without cognitive symptoms. These findings could improve trial recruitment for preventive treatments.
Researchers emphasize that p-tau217 levels alone are not definitive predictors. Factors like age, genetics, kidney function, obesity, and racial or ethnic backgrounds also influence dementia risk and biomarker levels. They call for larger, diverse studies with extended follow-up periods to enhance long-term risk predictions.
The FDA has approved the p-tau217 blood test for clinical use in the United States. In May 2025, the FDA approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test from Fujirebio as the first diagnostic tool to aid Alzheimer’s diagnosis.
Newsweek is seeking further information from study authors Rachel F. Buckley et al. on the findings published in JAMA, 2026.
Leave a Reply